Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG in Autoimmune Autonomic Ganglionopathy
NCT01522235Phase 3Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Feb 2012
- Primary completion
- May 2014
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune autonomic ganglionopathy (AAG) comparing IVIg group with Placebo Group (2 arms). Primary endpoint: Change in Systolic Blood Pressure During 60° Tilt (ΔSBP) at 6 weeks. Started Feb 2012; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
autoimmune autonomic ganglionopathy (AAG)
Beyond the preview
Go deeper on NCT01522235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01522235.